nach oben

Targeted Oncology

Erschienen in:

01.06.2009 | Review

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

verfasst von: Kamalesh Sankhala, Alain Mita, Kevin Kelly, Devalingam Mahalingam, Francis Giles, Monica Mita

Erschienen in: Targeted Oncology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Mammalian target of rapamycin (mTOR) has emerged as an important target for cancer therapy. Rapamycin has a distinct, well-documented toxicity profile and most of the toxicity data has been reported in patients with organ transplantation. Newer mTOR inhibitors have slightly different pharmacokinetic properties, yet they present toxicity profiles similar to rapamycin. Most of these toxicities are mild to moderate in severity and can be managed clinically by dose modification and supportive measures. Mucositis and pneumonitis are the most commonly reported toxicities, but they rarely lead to treatment discontinuation. Pathogenesis of pneumonitis is uncertain, but various hypotheses have been suggested, including cell-mediated immune response to the drug.

Hennessy BT et al (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988–1004CrossRefPubMed

Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12(18):5268–5272CrossRefPubMed

Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92(18):1472–1489CrossRefPubMed

MacDonald AS (2001) A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71(2):271–280CrossRefPubMed

Huang S, Houghton PJ (2002) Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 3(2):295–304PubMed

Hudes G et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281CrossRefPubMed

Raymond E et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22(12):2336–2347CrossRefPubMed

Mita MM et al (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26(3):361–367CrossRefPubMed

O'Donnell A et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10):1588–1595CrossRefPubMed

10.

Morelon E et al (2001) Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72(5):787–790CrossRefPubMed

11.

Lennon A et al (2001) Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation 72(6):1166–1167CrossRefPubMed

12.

Atkins MB, Stadler W et al (2002) A randomized double blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 21:36 Abstract

13.

Atkins MB et al (2006) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909–918CrossRef

14.

Duran I et al (2004) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42(12):1875–1880CrossRef

15.

Pham PT et al (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77(8):1215–1220CrossRefPubMed

16.

Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet 372(9637):449–456CrossRef

17.

Brattstrom C et al (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65(9):1272–1274CrossRefPubMed

18.

Kraemer FB et al (1998) Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways. Metabolism 47(5):555–559CrossRefPubMed

19.

Massy ZA et al (2000) Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A. Nephrol Dial Transplant 15(6):928CrossRefPubMed

20.

Hoogeveen RC et al (2001) Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 72(7):1244–250CrossRefPubMed

21.

Kahan BD (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356(9225):194–202CrossRefPubMed

22.

Hidalgo M et al (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12(19):5755–5763CrossRefPubMed

23.

23. Yee KW et al Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12(17):5165–5173

24.

Fraenkel M et al (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57(4):945–957CrossRefPubMed

25.

Tremblay F, Marette A (2001) Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276(41):38052–38060PubMed

26.

Galanis E et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23(23):5294–5304CrossRefPubMed

27.

Bellmunt J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19(8):1387–1392CrossRefPubMed

28.

Hong JC, Kahan BD (2000) Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69(10):2085–2090CrossRefPubMed

29.

Mita MM, Poplin E, Tap WD, Carmona A, Yonemoto L, Wages DS, Bedrosian CL, Rubin EH, Tolcher AW (2008) Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). J Clin Oncol 26:3509 abstractCrossRef

30.

Kneteman N, Babini R et al (2000) Sirolimus immunosuppression for liver transplantation in the presence of malignancy. XVIII International Congress of the Transplantation Society: Abstract

31.

Stallone G et al (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352(13):1317–1323CrossRefPubMed

32.

Stallone G et al (2008) Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. Transpl Int 21(9):825–832CrossRefPubMed

33.

Kahan BD, Camardo JS (2001) Rapamycin: clinical results and future opportunities. Transplantation 72(7):1181–1193CrossRefPubMed

34.

Groth CG et al (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European renal transplant study group. Transplantation 67(7):1036–1042CrossRefPubMed

35.

Kreis H et al (2000) Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69(7):1252–1260CrossRefPubMed

36.

Morales JM, Wramner H, Kreis D et al (2000) Sirolimus vs cyclosporin: a comparision of renal function over two years. XVIII International Congress of the Transplantation Society 140:0428 Abstract

37.

Chan S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23(23):5314–5322CrossRefPubMed

38.

Witzig TE et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23(23):5347–5356CrossRefPubMed

39.

Amato RJ et al (2006) A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Meeting Abstracts) 24((18_suppl)):4530

40.

Chawla SP, Staddon AP, Schuetze SM, D'Amato GZ, Blay JY, Sankhala KK, Daly ST, Rivera VM, Demetri GD (2006) Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol 24(18S):9505

41.

Rizzieri DA et al (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14(9):2756–2762CrossRefPubMed

Titel: The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents
verfasst von: Kamalesh Sankhala
Alain Mita
Kevin Kelly
Devalingam Mahalingam
Francis Giles
Monica Mita
Publikationsdatum: 01.06.2009
Verlag: Springer-Verlag
Erschienen in: Targeted Oncology / Ausgabe 2/2009
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-009-0107-z

Springer Medizin

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors

Indexing: the north face

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

Skin toxicities associated with epidermal growth factor receptor inhibitors

QT interval prolongation among patients treated with angiogenesis inhibitors

Maximum tolerated dose: clinical endpoint for a bygone era?

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie